Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 193–216 of 297
Mirroring tissue senescence in human biofluids
Researchers have developed a non-invasive urine-based biomarker panel to monitor cellular senescence and track the efficacy of senolytic therapies. This approach enables real-time assessment of senescent cell burden without tissue biopsy, creating a practical pathway for personalized intervention monitoring in aging-related disease.
The puzzling duality of mesenchymal stem cells and adipocytes in bone marrow and ageing
Mesenchymal stem cells in bone marrow show contradictory roles in aging—they support bone regeneration but accumulate as fat cells that displace bone-forming capacity. This duality reveals why bone density declines despite maintained stem cell populations, a critical mechanism in skeletal aging.
Mitochondrial repair approach targets muscle loss in aging
Istesso has initiated a Phase 2 trial of leramistat, a mitochondrial complex I modulator designed to restore muscle repair capacity in sarcopenia patients. The therapy represents a shift from symptom management toward regenerative intervention, addressing a condition affecting one in three adults over 60 with no currently approved treatments.
Silencing Growth Hormone Has Strong Effects in Mouse Brains
Suppressing growth hormone signaling in adipose tissue of aged mice preserved cognitive function, reduced neuroinflammation and cellular senescence, and restored neural firing patterns to near-youthful levels. This demonstrates adipose tissue as a peripheral regulator of brain aging independent of systemic growth hormone levels.
Building a ‘Swiss Army Knife’ longevity drug
LinkGevity is developing a small-molecule therapeutic targeting necrosis—uncontrolled cell death—as an upstream driver of multiple age-related diseases. By intervening at this central physiological node, the approach aims to address degenerative change across chronic conditions simultaneously rather than treating diseases individually.
Some Researchers Choose Replacement Over Repair in Aging
Replacement-based interventions—substituting damaged cells, tissues, organs, and physiological systems with biological or synthetic alternatives—are emerging as a pragmatic complement to endogenous repair strategies in aging research. Multiple research organizations are advancing clinical applications ranging from stem cell therapies for structural injuries to bioprinted organs and genetic replacements derived from long-lived species.
The HIF‐1α Pathway Regulates Satellite Cell Fate During Aging Through Histone Lactylation
Pharmacological reactivation of HIF-1α signaling in aged satellite cells restores lactate-driven epigenetic remodeling and shifts cells from senescence toward a regenerative state, with treated cells demonstrating enhanced myogenic capacity and increased ATP production. This identifies a metabolic-epigenetic axis relevant to age-related muscle decline and suggests a therapeutic target for sarcopenia.
Dual gene therapy targets muscle aging
Unlimited Bio has initiated a Phase 1/2a clinical trial combining AAV9-Follistatin and VEGF plasmid gene therapy to address age-related muscle loss and vascular insufficiency. The dual approach targets both muscle growth capacity and the circulatory support system that sustains muscle function—a systems-level intervention designed to address interconnected aspects of aging.
Restoring Lysosomal Clearance Targets Parkinson's Root Cause
Researchers identified a protein mechanism that restores lysosomal clearance of alpha-synuclein, the pathogenic protein in Parkinson's disease. This addresses a fundamental aging problem: the cell's declining ability to eliminate misfolded proteins, which accelerates neurodegeneration when these proteins accumulate and further impair cellular cleanup systems.
AI regenerative medicine targets skin recovery
ROKIT Healthcare presented two-year clinical data on AI-driven bioprinting for skin cancer reconstruction using patients' own fat cells, demonstrating 0% recurrence, restored function and sensation, and minimal scarring. This represents a shift in how medicine approaches post-surgical recovery—from wound closure alone to restoration of tissue architecture and sensory integrity.
Muscle preservation emerges as critical GLP-1 treatment frontier
NorthStrive Biosciences has filed patent applications for two distinct muscle-preservation technologies—a peptide (EL-22) and an engineered microorganism platform (EL-32)—designed to mitigate lean mass loss during GLP-1 and multi-hormone weight-loss treatment. This represents a shift in obesity medicine from maximizing weight loss alone to preserving metabolic and structural integrity during pharmacological intervention.
Gene therapy reprograms cartilage cells without grafting
FibroBiologics obtained European patent protection for a gene therapy approach that instructs fibroblast cells to differentiate into cartilage-producing cells using Sox9 and related genetic sequences. The technology addresses cartilage degradation through cellular reprogramming rather than surgical grafting, with potential application across orthopedic and spinal conditions.
Adipose Gene Therapy Cuts Chronic Disease Dosing Burden
Remedium Bio secured $10 million in Series A funding to advance a platform technology that converts subcutaneous fat tissue into sustained protein-production sites, reducing treatment frequency from multiple injections to single administrations with adjustable dosing. The approach targets cardiometabolic and chronic disease management through controlled gene expression.
Liver's dual protein-sensing pathways shift with age
Low-protein diets trigger distinct molecular responses in the liver during aging, mediated both through and independent of FGF21 signaling. This dual-pathway mechanism reveals how nutrient restriction at the transcriptomic level may influence metabolic adaptation and longevity outcomes across the lifespan.
The Immunogenicity of Human Senescent Cells Is Dependent on the Senescence Inducer and Cell Type
Senescent cell immunogenicity varies substantially by cell type and the trigger that induced senescence. RAS-induced senescent myoblasts activated immune responses, while senescent fibroblasts, endothelial cells, and lung progenitors showed limited or no immunogenicity despite expressing senescence markers.
Gene therapy for aging advances to animal trials
Genflow Biosciences secured overwhelming shareholder approval for board leadership and capital authorization to advance its gene therapy pipeline targeting age-related diseases. The company is progressing GF-1002, its lead therapeutic candidate, through preclinical validation and early clinical evaluation in animal models with plans for human trials in metabolic disease.
Vitamin K2 Extends Lifespan by Alleviating Mitochondrial Stress via the JNK‐1/SIR‐2.1/DAF‐16 Signaling Axis in Caenorhabditis elegans
Vitamin K2 at optimal concentrations (5 μM) extends lifespan in C. elegans by activating a signaling pathway that protects mitochondria from oxidative stress, maintains ATP production, and enhances cellular stress resistance. This mechanism operates through preservation of mitochondrial function and reduction of reactive oxygen species accumulation.
Gene therapy replaces repeated injections with single-dose adipocyte platform
Remedium Bio has secured $10 million in Series A funding to advance subcutaneous gene therapies designed to produce therapeutic proteins from fat tissue for multi-year duration with adjustable dosing. The platform targets replacement of repeated protein injections with single-administration gene therapy for cardiometabolic and chronic disease applications.
Why Fast-Cycling Skin Cells Decrease With Age
Fibulin-5, an extracellular matrix protein that declines with age, regulates fast-cycling skin cell populations through the YAP signaling pathway. Mice lacking fibulin-5 exhibit accelerated skin aging phenotypes, including loss of regenerative cell populations and compromised dermal-epidermal integrity, suggesting this protein may be central to maintaining skin renewal capacity across the lifespan.
Why Fast-Cycling Skin Cells Decrease With Age
Fibulin-5, an extracellular matrix protein that declines with age, maintains populations of fast-cycling skin cells through YAP signaling. Mice lacking fibulin-5 exhibit accelerated skin aging phenotypes, including loss of fast-cycling cells and compromised epidermal-dermal junction integrity, mirroring natural aging processes.
Autophagy Collapse Drives Sepsis Risk in Aging Kidneys
Aging kidneys show impaired autophagy activation—a cellular cleanup mechanism—making them vulnerable to sepsis-induced acute kidney injury. Restoring autophagy through TFEB activation or pharmacological intervention partially reverses this age-related deficit and protects against septic injury in aged tissues.
Mitorubin, berberrubine-based compounds that improve mitochondrial function, exhibit cardioprotective effects against age-related cardiac dysfunction
Mitorubin, a berberrubine-derived compound, restores mitochondrial function and protects cardiac tissue from age-related deterioration. This addresses a primary mechanism of cardiovascular aging by targeting energy production capacity at the cellular level.
Pandorum Technologies raises $18M Series B to scale regenerative therapies
Pandorum Technologies secured $18 million in Series B funding to scale its programmable tissue engineering platform for wound healing and organ repair. The capital accelerates manufacturing, regulatory pathways, and clinical partnerships for regenerative therapies addressing tissue damage and loss.
Life Bio’s Trial: Is the FDA Warming to Rejuvenation?
Life Biosciences' ER-100, a cellular reprogramming therapy, entered FDA-cleared human trials in January 2026 for optic nerve disorders, marking the first regulatory authorization of a rejuvenation-based intervention. The trial structure and emergence of the Plausible Mechanism Pathway suggest regulatory willingness to advance age-reversal technologies through disease-specific endpoints, potentially accelerating clinical translation of cellular reprogramming across multiple organ systems.